Amsurg stock receives ‘buy’ rating by Mizuho analysts: 5 points

Mizuho analysts rated Amsurg’s stock as “buy” on June 26, according to Directors Talk.

Advertisement

Here are five points:

1. The Mizuho analysts set a price target of $95 on Amsurg’s stock.

2. Mizuho predicts a potential upside of 20.4 percent from Amsurg’s opening price of $78.88.

3. With a 50-day moving average of $78.60, Amsurg has a 200-day moving average of $77.36.

4. Amsurg stock’s 52-week high is $87.42 and its 52-week low is $54.11.

5. In the past 90 trading days, Amsurg’s share price increased 9.41 points.

More articles on transactions & valuation:
Compass sells Bay Area Physicians Surgery Center following successful turnaround: 5 things to know
Surgery Partners acquires Riverside Pain Physicians; Cantor Fitzgerald analyst claims AmSurg’s latest merger leaves its ASC business’ future hanging in the balance & more — 6 key notes on ASC companies
4 points on Syracuse Orthopedic Specialists meeting patient demand through its orthopedic-driven ASC

Advertisement

Next Up in ASC Transactions & Valuation Issues

  • Lawmakers in South Carolina are considering banning noncompete clauses in physician contracts with a newly introduced bill, The State reported…

  • New Hyde Park, N.Y.-based Northwell Health’s Peconic Bay Medical Center has opened a new $5 million women’s multispecialty center in…

  • Stark law enforcement is intensifying as the Justice Department recovered a record $6.8 billion under the False Claims Act and…

Advertisement

Comments are closed.